KornhaberRA, Abu-QamarMZ, WilsonA (2013) Applying for ethical approval for a national multisite study: The challenges and barriers. Monash Bioeth Rev30, 103–122.
2.
RosenAC, AshfordJW, PerryG (2014) Ethics review as a catalyst for progress. J Alzheimers Dis40, 233–235.
3.
KimSY, WilsonR, De VriesR, KimHM, HollowayRG, KieburtzK (2015) “It is not guaranteed that you will benefit”: True but misleading?Clin Trials12, 424–429.
4.
ZengLF, LiangWX, PanJK, CaoY, LiuJ, WangQ, WangL, ZouYP, WangKZ, KongLS, XieH, XuWH, LiWR, ZhaoW, MiSQ, ChenYB, ChengSY, LiXY, CaoQ, ZengX, WangNS (2016) Do Chinese researchers conduct ethical research and use ethics committee review in clinical trials of anti-dementia drugs? An analysis of biomedical publications originating from China. J Alzheimers Dis52, 813–823.
5.
RosenbergJ (2016) Approaches to increasing ethical compliance in China with drug trial standards of practice. J Alzheimers Dis52, 825–827.
6.
RosenbergJ, BauchnerH, BackusJ, De LeeuwP, DrazenJ, FrizelleF, GodleeF, HaugC, JamesA, LaineC, ReyesH, SahniP, ZhaoriG, International Committee of Medical Journal Editors (2013) The new ICMJE recommendations. Natl Med J India26, 258–259.
7.
TaljaardM, ChaudhrySH, BrehautJC, WeijerC, BoruchR, DonnerA, EcclesMP, McRaeAD, SaginurR, ZwarensteinM, GrimshawJM (2014) Survey of consent practices in cluster randomized trials: Improvements are needed in ethical conduct and reporting. Clin Trials11, 60–69.
